Expression of Vimentin, p53, and Ki-67 in Urothelial Carcinoma of Urinary Bladder: Correlation with Histologic grade and Muscle Invasion
Md. Zahirul Islam
Lecturer Department of Pathology Sher-E-Bangla Medical College Barishal, Bangladesh Email: doctor.sajib.sbmc37@gmail.com
Shamim Ahamed
Assistant Professor Department of Pathology Bashundhara Ad-Din Medical College Dhaka, Bangladesh
Md. Harun Or Rashid
Lecturer Department of Pathology Shaheed Tajuddin Ahmad Medical College Gazipur, Bangladesh
Mashrufa Rahman
Assistant Professor Department of Pathology Anwer Khan Modern Medical College Dhaka, Bangladesh
Tanzila Afroze
Lecturer Department of Pathology Sir Salimullah Medical College
Keywords: Vimentin, Ki 67, p53, Urothelial carcinoma, Muscle invasion, Grade
Abstract
Background: Bladder cancer is one of the most common cancers with non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) being the two principal types. Biomarkers vimentin and Ki-67 play an important role in establishing tumor growth and potential prognostic value.
Objective: The study aimed to the monitoring of Vimentin, p53, and Ki-67 expression based on histologic grade and muscle invasion in bladder urothelial carcinoma.
Methods: A total of 60 bladder cancer patients, including NMIBC and MIBC patients, were being studied. Immunohistochemistry was performed to analyze the expression of vimentin and Ki-67. Statistical analysis included Pearson correlation and Chi-square tests to analyze correlations with clinicopathological parameters.
Results: Widespread expression of vimentin and Ki-67 was strongly associated with increased tumor grade, lymph node status, and poor overall survival. Increased vimentin and Ki-67 expression also showed a strong association with each other, suggesting perhaps a role in tumor aggressiveness and advancement.
Conclusion: The studies demonstrate that vimentin and Ki-67 are relevant biomarkers for prognosis in bladder cancer. Their expression levels may be employed for more accurate patient stratification and tailored treatment, and thus validation in larger, multi-center trials is warranted.
J Rang Med Col. March 2025; Vol.10, No.1:10-15
DOI: https://doi.org/10.3329/jrpmc.v10i1.81515